Hongene Biotech Pharmaceutical Ingredient Manufacturing Plant
Singapore-based Hongene Biotech is establishing its first European manufacturing facility in the Gödöllő Business Park. The greenfield investment aims to expand the production of nucleic acid-based pharmaceutical ingredients and active substances used by the international pharmaceutical industry. These materials play an important role in the manufacture of mRNA- and oligonucleotide-based therapeutics.
The development comprises pharmaceutical manufacturing buildings and supporting facilities. In addition to production areas, the complex will accommodate quality assurance, warehousing, utility infrastructure and environmental protection facilities.
Commissioned by Hongene Biotech Magyarország Kft., our team is responsible for the comprehensive design of the 14,270-square-metre facility. The project's engineering complexity lies in the specialised requirements of pharmaceutical production and the coordination of various manufacturing and supporting functions. Our design work therefore focuses on integrating architectural and multidisciplinary engineering solutions while taking the requirements of the production processes into account.
The investment, valued at approximately HUF 36 billion, is expected to create 150 high-value-added jobs in Gödöllő. With production primarily intended for export markets, the facility is expected to strengthen Hungary's role in the international pharmaceutical industry and contribute to the development of Europe's pharmaceutical supply chain.